Soluble CD23 measurement by CBA: a convenient and reliable quantification method in chronic lymphocytic leukemia.

about

Soluble CD23 measurement by CBA: a convenient and reliable quantification method in chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q43599780

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@en

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@nl

type

Item

label

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@en

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@nl

prefLabel

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@en

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@nl

P1476

Soluble CD23 measurement by CB ...... chronic lymphocytic leukemia.

@en

P2093

A Grelier

http://www.w3.org/2001/XMLSchema#string

F Nauwelaers

http://www.w3.org/2001/XMLSchema#string

M Le Garff-Tavernier

http://www.w3.org/2001/XMLSchema#string

M Sarfati

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Expression, regulation and function of human Fc epsilon RII (CD23) antigen

Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia.

Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA.

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Human IgE-binding factors.

CD23 antigen regulation and signaling in chronic lymphocytic leukemia.

P304

91-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CYTO.B.21135

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hélène Merle-Béral

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24150841

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte